Abstract: Dizal, a China-based commercial-stage biopharmaceutical company, is seeking an A+H listing. GS and Huatai are the joint sponsors. While our previous note covers the fundamentals of the company, in this note we look at its pipeline, latest results and A-H premium. We think the deal is worth following as the AstraZeneca licence of ZEGFROVY turned the company profitable in the third quarter.
DIZAL (JIANGSU) PHARMACEUTICAL, REMEGEN, Johnson & Johnson, Cullinan Therapeutics, Inc. Common Stock, SHANGHAI ALLIST PHARMACEUTICALS, ArriVent BioPharma, Inc. Common Stock, Eli Lilly, INNOVENT BIO, INNOCARE PHARMA, SHANGHAI JUNSHI BIOSCIENCES, JUNSHI BIO, BEONE MEDICINES, JIANGSU HENGRUI MEDICINE, HENGRUI PHARMA, LIVZON PHARMACEUTICAL, LIVZON PHARMA, Fosun Pharma, CANSINO BIOLOGICS, CANSINOBIO, Fudan-Zhangjiang Bio, FUDANZHANGJIANG
Research on Hong Kong and A+H equity offerings, from the first filing to the aftermarket. Coverage includes pre-IPO early thoughts on the business and valuation, analysis of the final deal terms and cornerstone investors, and updates as new prospectus versions are filed.
Interested in the full report? Get in touch with our team.
We will review your request. Once approved, the report will be sent to your company email.
Thank you! We will review your request and email the report to you, usually within 1 business day.